Lung Cancer | Specialty

Dr. Pearlstone on Technological Challenges

March 8th 2011

Race Does Not Predict Survival in Black Lung Cancer Patients

March 8th 2011

Researchers have ruled out race as a prognostic factor for overall survival (OS) in black patients with a lung cancer diagnosis.

From the Editor: Electronic Alerts Would Help Oncologists Manage Therapy

March 7th 2011

It was not so long ago that designing an optimal treatment plan for an individual cancer patient required only a confirmed histologic/morphologic diagnosis of a particular tumor type and appropriate staging, which was surgically based in most solid tumors.

Priming the Pipeline: 5 New Drugs in Works

March 7th 2011

There's been a flurry of activity in recent weeks when it comes to oncology drug filings at the FDA. While every application is unique, the agency is required to decide within 60 days whether a new drug application (NDA) will move forward for a full review.

John Theurer Cancer Center Opens New Comprehensive Facility

March 4th 2011

The John Theurer Cancer Center (JTCC) at Hackensack University Medical Center in New Jersey, one of the largest cancer centers in the United States

Interview With Siddhartha Mukherjee, Author of The Emperor of All Maladies

March 4th 2011

Siddhartha Mukherjee, MD, discusses his book The Emperor of All Maladies.

Maintenance Therapy in Advanced Non-Small Cell Lung Cancer: Before We Accept This Treatment Paradigm, Let's Critically Evaluate and Interpret the Data

March 4th 2011

Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality in the United States.

Avastin Alarm

March 4th 2011

A meta-analysis of randomized controlled trials revealed treatment-related fatalities were 1.5 times higher for combination treatment with Avastin (bevacizumab) and chemotherapy versus chemotherapy alone

Adjuvant Therapy for Non-Small Cell Lung Cancer: Impact of Recent Clinical Trials on Community Practice

March 2nd 2011

Non-small cell lung cancer (NSCLC) is diagnosed at an early stage, when it is amenable to surgical resection in approximately 20% to 25% of cases.

Inconclusive Lung Cancer Screenings Prompt Smokers to Quit

March 2nd 2011

Men who undergo lung cancer screening are more likely to stop smoking if the results are inconclusive than if they are negative, according to a team of researchers from Denmark.

Company Claims to Make Safer Smokeless Tobacco

March 2nd 2011

Star Scientific, a Virginia-based company, has petitioned the FDA to approve the sale of what it claims is a

Oncology Community Facing Severe Drug Shortages

December 19th 2010

Hospitals, pharmacists, and physicians across the United States are reporting shortages of critical anticancer drugs, including carboplatin, cisplatin, dacarbazine, fludarabine, and cytarabine.

BIO-BUZZ: Inhibition of Angiogenesis with Bevacizumab Shows Promise in the Treatment of Recurrent or Advanced Non%u2013Small-Cell Lung Cancer

August 17th 2010

This year in the US, the American Cancer Society estimates that lung cancer will kill more people than breast, prostate, colon, liver, and kidney cancers combined, making it the leading cause of cancer death among Americans.

Amgen Reports Aranesp Does Not Increase Deaths

August 11th 2010

The results of Amgen's %u201C145 study%u201D of Aranesp in patient's with late-stage small-cell lung cancer (SCLC) are released.

Active Symptom Control With or Without Chemotherapy in the Treatment of Malignant Pleural Mesothelioma

July 8th 2010

Chemotherapy is widely used in the treatment of malignant mesothelioma, but it has never been compared in a randomized trial with active symptom control (ASC) alone.

Highlighting Advances in Lung Cancer

June 30th 2010

Lung cancer is the second most common cancer and the most common cause of cancer-related death in both men and women in the US. At the12th World Conference on Lung Cancer (WCLC), the world%u2019s top lung cancer specialists convened to present and discuss the latest research in this disease. Key themes included accurate targets, new combinations of drugs to reduce toxicity, and strategies to improve outcomes.

Updates from Oncology Meetings

June 30th 2010

Oncology & Biotech News provides updates from major oncology meetings because symposia remain an important means for disseminating new data. This issue, we highlight two important meetings: 2007 Breast Cancer Symposium (in San Francisco) and the World Conference on Lung Cancer (in Korea).

GPS for the Body: Treating a Moving Target

February 25th 2009

A common treatment option for prostate cancer is radiation therapy, which is as effective in treating the disease as surgical removal of the prostate.

50th Annual Meeting of the American Society of Hematology

January 27th 2009

Highlights from the 50th Annual Meeting of the American Society of Hematology.

Anti-Lung Cancer Compound ASA404 Progresses to Phase III

November 17th 2008

A pivotal phase III study is currently underway to evaluate the efficacy and safety of Novartis’ novel anti-cancer compound ASA404 in patients with non–small cell lung cancer (NSCLC).